These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 23733004)

  • 21. Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London.
    Mohsen AH; Murad S; Easterbrook PJ
    HIV Med; 2005 May; 6(3):206-15. PubMed ID: 15876288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mathematically modelling the spread of hepatitis C in injecting drug users.
    Corson S; Greenhalgh D; Hutchinson S
    Math Med Biol; 2012 Sep; 29(3):205-30. PubMed ID: 21900152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010.
    Wiessing L; Likatavicius G; Hedrich D; Guarita B; van de Laar MJ; Vicente J
    Euro Surveill; 2011 Dec; 16(48):. PubMed ID: 22172300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus infection and related risk factors among injection drug users in Montenegro.
    Baćak V; Laušević D; Mugoša B; Vratnica Z; Terzić N
    Eur Addict Res; 2013; 19(2):68-73. PubMed ID: 23006531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of needle exchange programs in HIV prevention.
    Vlahov D; Junge B
    Public Health Rep; 1998 Jun; 113 Suppl 1(Suppl 1):75-80. PubMed ID: 9722812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors.
    Loebstein R; Mahagna R; Maor Y; Kurnik D; Elbaz E; Halkin H; Olchovsky D; Ezra D; Almog S
    Isr Med Assoc J; 2008 Nov; 10(11):775-8. PubMed ID: 19070285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Could the CARE-SHAKTI intervention for injecting drug users be maintaining the low HIV prevalence in Dhaka, Bangladesh?
    Foss AM; Watts CH; Vickerman P; Azim T; Guinness L; Ahmed M; Rodericks A; Jana S
    Addiction; 2007 Jan; 102(1):114-25. PubMed ID: 17207129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Demographic, risk behaviour and personal network variables associated with prevalent hepatitis C, hepatitis B, and HIV infection in injection drug users in Winnipeg, Canada.
    Wylie JL; Shah L; Jolly AM
    BMC Public Health; 2006 Sep; 6():229. PubMed ID: 16970811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prevalence of HIV infection among drug users in Zuid-Limburg].
    Wiessing LG; Houweling H; Meulders WA; Cerdá E; Jansen M; Sprenger MJ
    Ned Tijdschr Geneeskd; 1995 Sep; 139(38):1936-40. PubMed ID: 7477534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs.
    Zeiler I; Langlands T; Murray JM; Ritter A
    Drug Alcohol Depend; 2010 Aug; 110(3):228-33. PubMed ID: 20430537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A nested-epidemic model for the spread of hepatitis C among injecting drug users.
    Esposito N; Rossi C
    Math Biosci; 2004; 188():29-45. PubMed ID: 14766092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determinants of injection drug user (IDU) syringe sharing: the relationship between availability of syringes and risk network member characteristics in Winnipeg, Canada.
    Shaw SY; Shah L; Jolly AM; Wylie JL
    Addiction; 2007 Oct; 102(10):1626-35. PubMed ID: 17854339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia.
    Rhodes T; Platt L; Judd A; Mikhailova LA; Sarang A; Wallis N; Alpatova T; Hickman M; Parry JV
    Int J STD AIDS; 2005 Nov; 16(11):749-54. PubMed ID: 16303071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence and associated clinical characteristics of hepatitis B, C, and HIV infections among injecting drug users in Korea.
    Min JA; Yoon Y; Lee HJ; Choi J; Kwon M; Kim K; Lee CU; Kim DJ; Yun H
    J Med Virol; 2013 Apr; 85(4):575-82. PubMed ID: 23364858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention.
    Koester S; Glanz J; Barón A
    AIDS Behav; 2005 Mar; 9(1):27-39. PubMed ID: 15812611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study.
    Vickerman P; Hickman M; Judd A
    Int J Epidemiol; 2007 Apr; 36(2):396-405. PubMed ID: 17218325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV and HCV infection among injecting drug users.
    Hagan H; Des Jarlais DC
    Mt Sinai J Med; 2000; 67(5-6):423-8. PubMed ID: 11064493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users.
    Devi KhS; Brajachand N; Singh HL; Singh YM
    J Commun Dis; 2005 Mar; 37(1):73-7. PubMed ID: 16637404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Difficulty accessing syringes and syringe borrowing among injection drug users in Bangkok, Thailand.
    Kerr T; Fairbairn N; Hayashi K; Suwannawong P; Kaplan K; Zhang R; Wood E
    Drug Alcohol Rev; 2010 Mar; 29(2):157-61. PubMed ID: 20447223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prevalence of hepatitis B, hepatitis C and HIV among injecting drug users treated outpatiently and in therapeutic community in Brod-Posavina County, Croatia].
    Kolovrat A; Jurisić I; Marić Z; Cvitković A
    Acta Med Croatica; 2010 Oct; 64(4):287-96. PubMed ID: 21688612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.